Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-70033093 versus enoxaparin for venous thromboembolism prevention after elective total knee replacement
MOH_2019-09-09_007218Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of milvexian and enoxaparin in venous thromboembolism (VTE) (6 arms), sponsored by Janssen Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
milvexianenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2019-09-09_007218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-09_007218.